Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma
Autore:
Rajkumar, SV; Burch, PA; Nair, S; Dinapoli, RP; Scheithauer, B; OFallon, JR; Etzell, PS; Leitch, JM; Morton, RF; Marks, RS;
Indirizzi:
Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Fdn, Rochester, MN 55905 USA Geisinger Clin, Oncol Program, Danville, PA USA Geisinger Clin Danville PA USA ger Clin, Oncol Program, Danville, PA USA Meritcare Hosp CCOP, Fargo, ND USA Meritcare Hosp CCOP Fargo ND USAMeritcare Hosp CCOP, Fargo, ND USA Iowa Oncol Res Assoc CCOP, Des Moines, IA USA Iowa Oncol Res Assoc CCOP Des Moines IA USA soc CCOP, Des Moines, IA USA
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 2, volume: 22, anno: 1999,
pagine: 168 - 171
SICI:
0277-3732(199904)22:2<168:PINCCT>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEUKEMIA;
Keywords:
brain tumors; 2-chlorodeoxyadenosine; chemotherapy; recurrent gliomas; clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Marks, RS Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 05 USA
Citazione:
S.V. Rajkumar et al., "Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma", AM J CL ONC, 22(2), 1999, pp. 168-171

Abstract

There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chloradeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible, Protocol treatment consisted of 2-chlorodeoxyadenosine 7.0 mg/m(2) intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2-chlorodeoxyadenosine was reduced to 5.6 mg/m(2) on days I through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered inthe study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activityin patients with recurrent gliomas was established.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:14:43